Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
London, UK, 7 January 2021 - Yaqrit, a clinical stage life sciences company focused on developing potentially innovative treatments for patients with advanced liver disease in areas of high unmet medical need, today announces preliminary results from its randomised controlled clinical trials for two potential therapies from its pipeline of product candidates designed to address each stage of liver disease, from diagnosis of decompensated c
Yaqrit Discovery Ltd
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
Orally-administered,
non-absorbable engineered carbon, Carbalive
™, was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis
Safety of novel dual filtration system, Dialive
™, confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group
The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group.
(2)
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation
The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis
Planning for pivotal trials to support approval in Europe is now under way
7
th January, 2021 - The
CARBALIVE Consortium( CARBALIVE or the Consortium ) is pleased to announce positive data from the Phase 2 equivalent randomised, double-blind clinical trial of Carbalive, a product candidate for the treatment of patients with decompensated cirrhosis. Carbalive is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeability, preventing them from
Dry January : Est-ce efficace d arrêter l alcool pendant un mois ? maxisciences.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from maxisciences.com Daily Mail and Mail on Sunday newspapers.